We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
-6.73%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.47B
AUM Growth
-$295M
Cap. Flow
-$1.59B
Cap. Flow %
-35.66%
Top 10 Hldgs %
41.85%
Holding
141
New
13
Increased
10
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$48.9M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$45.3M
3
LUNG icon
Pulmonx
LUNG
+$34.3M
4
AHCO icon
AdaptHealth
AHCO
+$25.6M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$23.7M

Top Sells

Rank Stock Value
1
APR
Apria, Inc. Common Stock
APR
+$54M
2
GKOS icon
Glaukos
GKOS
+$41.9M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$40.1M
4
CNC icon
Centene
CNC
+$36.9M
5
PCRX icon
Pacira BioSciences
PCRX
+$35.9M

Sector Composition

Rank Sector Weight
1 Healthcare 54.44%
2 Financials 1.5%
3 Consumer Discretionary 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLU
26
DELISTED
BELLUS Health Inc.
BLU
$25.3M 0.56%
3,672,808
+1,223,808
+50% +$7.88M
LRMR icon
27
Larimar Therapeutics
LRMR
$384M
$23.6M 0.53%
5,830,249
– –
RVMD icon
28
Revolution Medicines
RVMD
$39.6B
$22.7M 0.51%
891,587
– –
MRTX
29
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$22.2M 0.5%
270,000
+182,000
+207% +$18.6M
GKOS icon
30
Glaukos
GKOS
$9.21B
$21.4M 0.48%
369,514
-791,900
-68% -$41.9M
DAWN
31
DELISTED
Day One Biopharmaceuticals
DAWN
$20.7M 0.46%
2,086,449
-116,084
-5% -$1.53M
GDRX icon
32
GoodRx Holdings
GDRX
$1.06B
$18.9M 0.42%
+979,106
New +$22.5M
NUVB icon
33
Nuvation Bio
NUVB
$2.02B
$18.8M 0.42%
3,577,233
– –
OM icon
34
Outset Medical
OM
$77.9M
$18.2M 0.41%
26,708
– –
IMGN
35
DELISTED
Immunogen Inc
IMGN
$16.5M 0.37%
+3,470,675
New +$19.2M
BCRX icon
36
BioCryst Pharmaceuticals
BCRX
$2.36B
$16.5M 0.37%
1,012,000
-674,140
-40% -$10.8M
DALS
37
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$15.5M 0.35%
1,600,000
– –
PROF
38
Profound Medical
PROF
$249M
$15.4M 0.34%
1,713,797
– –
ALEC icon
39
Alector
ALEC
$167M
$15M 0.34%
1,055,192
– –
XLO icon
40
Xilio Therapeutics
XLO
$58.4M
$14.7M 0.33%
148,478
-5,384
-3% -$852K
SWTX
41
DELISTED
SpringWorks Therapeutics
SWTX
$14.1M 0.32%
249,988
-202,012
-45% -$11.6M
EOLS icon
42
Evolus
EOLS
$377M
$13.8M 0.31%
+1,229,234
New +$10.5M
KALV
43
DELISTED
KalVista Pharmaceuticals
KALV
$12.2M 0.27%
830,472
-344,659
-29% -$4.95M
COGT icon
44
Cogent Biosciences
COGT
$6.68B
$12M 0.27%
1,601,000
– –
MRUS
45
DELISTED
Merus
MRUS
$11.6M 0.26%
437,000
– –
KNTE
46
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$11.1M 0.25%
985,568
– –
APEN
47
DELISTED
Apollo Endosurgery, Inc.
APEN
$10.6M 0.24%
1,750,000
– –
SRSA
48
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$9.9M 0.22%
999,999
– –
EUCR
49
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$9.84M 0.22%
999,999
– –
SNRH
50
DELISTED
Senior Connect Acquisition Corp. I Class A Common Stock
SNRH
$9.82M 0.22%
1,000,000
– –
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q1 2022 Portfolio in Review

As of Q1 2022, Deerfield Management held 141 positions worth $4.47B, down 6.2% from $4.77B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management withdrew a net $1.59B in Q1 2022, closing 19 positions and reducing 16 holdings. Its most notable exit was Apria, Inc. Common Stock, an estimated $54M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, down from 63% a quarter earlier, followed by Financials and Consumer Discretionary.

Against the trend, Deerfield Management opened a new position in Gilead Sciences worth $45.5M.

  • Deerfield Management's largest Q1 2022 buy was Gilead Sciences: 765,489 shares worth $45.5M.
  • Deerfield Management added most to Pulmonx in Q1 2022, an estimated $34.3M increase.
  • Deerfield Management's biggest Q1 2022 reduction was Glaukos, cutting an estimated $41.9M.
  • Deerfield Management fully exited Apria, Inc. Common Stock in Q1 2022, selling an estimated $54M.
  • Deerfield Management's ten largest holdings make up 42% of its $4.47B portfolio in Q1 2022.
  • Deerfield Management opened 13 new positions and closed 19 in Q1 2022.
  • Deerfield Management's portfolio value fell 6.2% quarter-over-quarter to $4.47B.

Based on Deerfield Management's 13F filing for Q1 2022, filed 16 May 2022.